Novonesis Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
Novonesis has a total shareholder equity of €11.0B and total debt of €2.0B, which brings its debt-to-equity ratio to 18.1%. Its total assets and total liabilities are €15.3B and €4.2B respectively. Novonesis's EBIT is €525.0M making its interest coverage ratio 15.7. It has cash and short-term investments of €260.8M.
Anahtar bilgiler
18.1%
Borç/özkaynak oranı
€1.99b
Borç
Faiz karşılama oranı | 15.7x |
Nakit | €260.80m |
Eşitlik | €11.01b |
Toplam yükümlülükler | €4.25b |
Toplam varlıklar | €15.25b |
Son finansal sağlık güncellemeleri
These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well
Sep 27Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?
Jun 24Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?
Mar 26Is Novozymes (CPH:NZYM B) Using Too Much Debt?
Dec 23These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well
Sep 13Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly
Jun 13Recent updates
These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well
Sep 27An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued
Sep 05Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively
Jul 09Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?
Jun 24Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)
May 02Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively
Apr 07Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?
Mar 26Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?
Mar 12Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues
Feb 04Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)
Jan 29Is Novozymes (CPH:NZYM B) Using Too Much Debt?
Dec 23Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture
Dec 05A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)
Oct 14These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well
Sep 13The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence
Aug 29Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)
Jul 13Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly
Jun 13Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital
May 29Estimating The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)
Apr 12Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: NSIS B's short term assets (€1.8B) exceed its short term liabilities (€1.6B).
Uzun Vadeli Yükümlülükler: NSIS B's short term assets (€1.8B) do not cover its long term liabilities (€2.6B).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: NSIS B's net debt to equity ratio (15.7%) is considered satisfactory.
Borcun Azaltılması: NSIS B's debt to equity ratio has reduced from 36.2% to 18.1% over the past 5 years.
Borç Kapsamı: NSIS B's debt is well covered by operating cash flow (44.8%).
Faiz Kapsamı: NSIS B's interest payments on its debt are well covered by EBIT (15.7x coverage).